Caliper Life Sciences, (Hopkinton, Mass.) will begin using SRU Biosystems’ label-free BIND technology to offer new functional assays as part of its Discovery Alliances and Services.
BIND technology, developed by SRU Biosystems, Woburn, Mass., provides researchers with an ultra-high throughput screening and profiling system for cell-based and biochemical assays. BIND technology for cell-based assays offers an orthogonal screening tool to access new hits and lead molecules that are not detected by other systems, including compounds that undergo G-protein switching, non-G protein coupled pathways, inverse and partial agonists, and receptor desensitization.
The screening platform is robust and can be applied to both over-expressed and endogenous receptors, and can be used with low numbers of primary cells. The technology can also used for receptor profiling on native cells, due to the high sensitivity of the response. Lastly, the technology provides a way to easily screen Gi-coupled GPCR targets and ion channels, which have been traditionally difficult to assess.
“Caliper Life Sciences … is uniquely positioned to offer BIND technology as a contract service to the biotechnology and pharmaceutical communities. They have tremendous knowledge utilizing innovative technologies to advance drug discovery and will provide an outstanding new service to the drug discovery industry,” said Rick Wagner, PhD, President and CEO of SRU Biosystems.
SRU Biosystems’ label-free BIND technology can be used for complex cellular assays such as GPCR pathway analysis, ion channel assays and cell adhesion assays; as well as biochemical assays, such as protein-protein binding, enzyme assays, and fragment and small molecule screening. These applications have been utilized in exploring assay development, 1536-well high throughput screening, and lead profiling.
SRU anticipates a continued expansion of its label-free BIND products, creating new assay capabilities.
Date: February 1, 2010
Source: SRU Biosystems
This news was published in Drug Discovery & Development magazine: Vol. 13, No. 1, January/February, 2010, p. 14.
Filed Under: Drug Discovery
